BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sikov WM. Assessing the role of platinum agents in aggressive breast cancers. Curr Oncol Rep 2015;17:3. [PMID: 25665554 DOI: 10.1007/s11912-014-0428-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
Number Citing Articles
1 Torrisi R, Zuradelli M, Agostinetto E, Masci G, Losurdo A, De Sanctis R, Santoro A. Platinum salts in the treatment of BRCA-associated breast cancer: A true targeted chemotherapy? Critical Reviews in Oncology/Hematology 2019;135:66-75. [DOI: 10.1016/j.critrevonc.2019.01.016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
2 He X, Dai X, Ji J, Liu H, Shi G, Yeung SJ. Nine-Year Median Follow-up of Ccardiotoxicity and Efficacy of Trastuzumab Concurrently With Anthracycline-Based and Anthracycline-Free Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer Patients. Clin Breast Cancer 2021:S1526-8209(21)00136-1. [PMID: 34312098 DOI: 10.1016/j.clbc.2021.05.008] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Villamar Cruz O, Prudnikova TY, Araiza-Olivera D, Perez-Plasencia C, Johnson N, Bernhardy AJ, Slifker M, Renner C, Chernoff J, Arias-Romero LE. Reduced PAK1 activity sensitizes FA/BRCA-proficient breast cancer cells to PARP inhibition. Oncotarget 2016;7:76590-603. [PMID: 27740936 DOI: 10.18632/oncotarget.12576] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
4 Pattarawat P, Hunt JT, Poloway J, Archibald CJ, Wang HR. A triple combination gemcitabine + romidepsin + cisplatin to effectively control triple-negative breast cancer tumor development, recurrence, and metastasis. Cancer Chemother Pharmacol 2021;88:415-25. [PMID: 34043046 DOI: 10.1007/s00280-021-04298-y] [Reference Citation Analysis]
5 Manahan ER, Kuerer HM, Sebastian M, Hughes KS, Boughey JC, Euhus DM, Boolbol SK, Taylor WA. Consensus Guidelines on Genetic` Testing for Hereditary Breast Cancer from the American Society of Breast Surgeons. Ann Surg Oncol 2019;26:3025-31. [PMID: 31342359 DOI: 10.1245/s10434-019-07549-8] [Cited by in Crossref: 62] [Cited by in F6Publishing: 48] [Article Influence: 20.7] [Reference Citation Analysis]
6 Zhang R, Song XQ, Liu RP, Ma ZY, Xu JY. Fuplatin: An Efficient and Low-Toxic Dual-Prodrug. J Med Chem 2019;62:4543-54. [PMID: 31002510 DOI: 10.1021/acs.jmedchem.9b00128] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
7 Toma M, Skorski T, Sliwinski T. DNA Double Strand Break Repair - Related Synthetic Lethality. Curr Med Chem 2019;26:1446-82. [PMID: 29421999 DOI: 10.2174/0929867325666180201114306] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
8 Ma ZY, Wang DB, Song XQ, Wu YG, Chen Q, Zhao CL, Li JY, Cheng SH, Xu JY. Chlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo. Eur J Med Chem 2018;157:1292-9. [PMID: 30195239 DOI: 10.1016/j.ejmech.2018.08.065] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
9 Huang J, Liu C, Duan S, Lin J, Luo Y, Tao S, Xing S, Zhang X, Du H, Wang H, Huang C, Wei G. Gigantol inhibits proliferation and enhances DDP-induced apoptosis in breast-cancer cells by downregulating the PI3K/Akt/mTOR signaling pathway. Life Sci 2021;274:119354. [PMID: 33737087 DOI: 10.1016/j.lfs.2021.119354] [Reference Citation Analysis]
10 Ramnaraign B, Altshuler E. Complete clinical response of a patient with BRCA1-mutant cervical esophageal squamous cell carcinoma treated with oxaliplatin-based chemotherapy highlights the importance of performing genomic profiling in cancer treatment. Current Problems in Cancer: Case Reports 2021;3:100069. [DOI: 10.1016/j.cpccr.2021.100069] [Reference Citation Analysis]
11 Makuloluwa AK, Khaji S, Bile Z, Shankar V. Chemotherapy-induced anterior necrotising scleritis: A case report. Am J Ophthalmol Case Rep 2016;3:36-8. [PMID: 29503905 DOI: 10.1016/j.ajoc.2016.06.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
12 Kern P, Kalisch A, von Minckwitz G, Pütter C, Kolberg HC, Pott D, Kurbacher C, Rezai M, Kimmig R. Neoadjuvant, anthracycline-free chemotherapy with carboplatin and docetaxel in triple-negative, early-stage breast cancer: a multicentric analysis of rates of pathologic complete response and survival. J Chemother 2016;28:210-7. [PMID: 26239282 DOI: 10.1179/1973947815Y.0000000061] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
13 Liang DH, Choi DS, Ensor JE, Kaipparettu BA, Bass BL, Chang JC. The autophagy inhibitor chloroquine targets cancer stem cells in triple negative breast cancer by inducing mitochondrial damage and impairing DNA break repair. Cancer Lett. 2016;376:249-258. [PMID: 27060208 DOI: 10.1016/j.canlet.2016.04.002] [Cited by in Crossref: 59] [Cited by in F6Publishing: 58] [Article Influence: 9.8] [Reference Citation Analysis]
14 Dhillon KK, Bajrami I, Taniguchi T, Lord CJ. Synthetic lethality: the road to novel therapies for breast cancer. Endocr Relat Cancer 2016;23:T39-55. [PMID: 27528623 DOI: 10.1530/ERC-16-0228] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
15 Egger SJ, Willson ML, Morgan J, Walker HS, Carrick S, Ghersi D, Wilcken N. Platinum-containing regimens for metastatic breast cancer. Cochrane Database Syst Rev 2017;6:CD003374. [PMID: 28643430 DOI: 10.1002/14651858.CD003374.pub4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
16 De Iuliis F, Taglieri L, Salerno G, Giuffrida A, Milana B, Giantulli S, Carradori S, Silvestri I, Scarpa S. The kinesin Eg5 inhibitor K858 induces apoptosis but also survivin-related chemoresistance in breast cancer cells. Invest New Drugs 2016;34:399-406. [PMID: 26994617 DOI: 10.1007/s10637-016-0345-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
17 Dréan A, Lord CJ, Ashworth A. PARP inhibitor combination therapy. Crit Rev Oncol Hematol 2016;108:73-85. [PMID: 27931843 DOI: 10.1016/j.critrevonc.2016.10.010] [Cited by in Crossref: 103] [Cited by in F6Publishing: 93] [Article Influence: 17.2] [Reference Citation Analysis]
18 Egger SJ, Chan MMK, Luo Q, Wilcken N. Platinum-containing regimens for triple-negative metastatic breast cancer. Cochrane Database Syst Rev 2020;10:CD013750. [PMID: 33084020 DOI: 10.1002/14651858.CD013750] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Huang L, Liu Q, Chen S, Shao Z. Cisplatin versus carboplatin in combination with paclitaxel as neoadjuvant regimen for triple negative breast cancer. Onco Targets Ther 2017;10:5739-44. [PMID: 29238206 DOI: 10.2147/OTT.S145934] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
20 Li ZY, Zhang Z, Cao XZ, Feng Y, Ren SS. Platinum-based neoadjuvant chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis. J Int Med Res 2020;48:300060520964340. [PMID: 33100072 DOI: 10.1177/0300060520964340] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Bignon L, Fricker JP, Nogues C, Mouret-Fourme E, Stoppa-Lyonnet D, Caron O, Lortholary A, Faivre L, Lasset C, Mari V, Gesta P, Gladieff L, Hamimi A, Petit T, Velten M. Efficacy of anthracycline/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers. Breast J 2018;24:269-77. [PMID: 28929593 DOI: 10.1111/tbj.12887] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]